PCM
GBIO

Prelude Capital Management’s Generation Bio GBIO Stock Holding History

Prelude Capital Management’s Portfolio GBIO Stock Details GBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,010
Closed -$74K – 1890
2022
Q1 		$74K Buy
+1,010
New +$58.5K ﹤0.01% 1452

Other funds holding GBIO

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
YCM
Yiheng Capital Management San Francisco, California $231M AUM 29.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Prelude Capital Management's GBIO Position: Q2 2022 in Review

Prelude Capital Management sold out of Generation Bio (GBIO) in Q2 2022, closing a stake of 1,010 shares — an estimated $74K sold.

Prelude Capital Management first reported a position in GBIO in Q1 2022 and held it in 1 quarter. The position peaked at $74K in Q1 2022. 91 funds tracked by Wall St. Rank hold GBIO as of Q2 2022.

  • Prelude Capital Management reported no remaining Generation Bio position as of Q2 2022 after selling out during the quarter.
  • Prelude Capital Management sold 1,010 Generation Bio shares in Q2 2022, an estimated $74K.
  • Prelude Capital Management first reported a position in Generation Bio in Q1 2022 and held it in 1 quarter.
  • Prelude Capital Management's Generation Bio position peaked at $74K in Q1 2022.
  • 91 funds tracked by Wall St. Rank held Generation Bio as of Q2 2022.

Based on Prelude Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.